ReAble, DJO merger gets FTC (Federal Trade Commission) go-ahead:
This article was originally published in Clinica
Executive Summary
ReAble Therapeutics' merger with musculoskeletal and vascular health specialist DJO Incorporated has received the green light from the US Federal Trade Commission, after it granted early termination of the required antitrust waiting period. The deal, which will see private equity company The Blackstone Group acquire Vista, California-based DJO and merge it with ReAble (see Clinica No 1265, p 11), is expected to close in the fourth quarter of 2007, and is worth approximately $1.6bn.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.